Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).
Kindmark
Henrik
H
Department of Medicine/Endocrine Oncology, University Hospital, Uppsala, Sweden.
Janson
Eva Tiensuu
ET
Gustavsson
Bengt
B
Eriksson
Camilla
C
Larsson
Gunnel
G
Granberg
Dan
D
Kozlowacki
Gordana
G
Skogseid
Britt
B
Welin
Staffan
S
Oberg
Kjell
K
Eriksson
Barbro
B
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000378:metabolism; D004701:Endocrine Gland Neoplasms / Q000188:drug therapy / Q000378:metabolism; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D017479:Receptors, Platelet-Derived Growth Factor